ST. LOUIS & WOODBURY, Minn.--(BUSINESS WIRE)--Meridian Medical Technologies, LLC (Meridian), a division of Kindeva Drug Delivery (Kindeva), has been awarded a $9.9M contract to supply DuoDote® to the Administration for Strategic Preparedness and Response (ASPR) within the United States (U.S.) Department of Health and Human Services. Meridian is a globally leading health security and chemical, biological, radiological, and nuclear (CBRN) medical countermeasure provider. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent antidote. Meridian supplies DuoDote® to U.S. and allied ministries of health and defense, as well as hospitals and civilian first responder agencies.
As part of its role in the federal response, ASPR ensures the availability and rapid deployment of lifesaving pharmaceuticals, antidotes, and other medical supplies and equipment necessary to counter the effects of biological, chemical, radiological, and nuclear threats, emerging infectious diseases, and natural disasters.
“Commercial partnerships are important to maintain critically necessary resources and capabilities that may be required to respond to future emergencies,” said Kindeva’s Commercial Head - Injectables and Health Security Business Units Tom Handel. “Meridian has a decades long history of providing medical countermeasures to military and public health agencies and civilian responders globally. Meridian is proud to serve as a solutions provider to help the U.S. prepare and respond to emergencies, support state and local preparedness activities, and ensure availability of critical medical assets to protect the health of Americans.”
About Kindeva Drug Delivery
Kindeva is a global contract development and manufacturing organization focused on drug-device combination products and a global health security leader that provides medical countermeasures to defense and health ministries around the world. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and intra/transdermal patches. Our service offerings span early-stage feasibility through commercial-scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our nine manufacturing, research, and development facilities located in the U.S. and U.K. For more information, please visit www.kindevadd.com.
